This limits external validity of our findings, as anti-TNF-α agents are also used for treatment of other autoimmune conditions, such as inflammatory bowel diseases, and are part of chemotherapeutic protocols in treatment of B-cell lymphomas. The gene discussed is TNF; the disease is B-cell non-Hodgkin lymphoma.